Literature DB >> 30307705

Epigenetic soluble epoxide hydrolase regulation causes endothelial dysfunction.

John D Imig1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30307705      PMCID： PMC6548442          DOI： 10.1111/apha.13203

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN： 1748-1708            Impact factor:   6.311


× No keyword cloud information.
  9 in total

1.  JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer.

Authors:  Yang Xiang; Ziqi Zhu; Gang Han; Xiaolei Ye; Bo Xu; Zhouchun Peng; Yuanjun Ma; Yi Yu; Hanqing Lin; Adele Pin Chen; Charlie Degui Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-28       Impact factor: 11.205

Review 2.  Epigenetics and cardiovascular disease.

Authors:  José M Ordovás; Caren E Smith
Journal:  Nat Rev Cardiol       Date:  2010-07-06       Impact factor: 32.419

Review 3.  Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research.

Authors:  Carlos M Ferrario
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2006-03       Impact factor: 1.636

4.  The histone demethylase Jarid1b mediates angiotensin II-induced endothelial dysfunction by controlling the 3'UTR of soluble epoxide hydrolase.

Authors:  Andrea E Vasconez; Patrick Janetzko; James A Oo; Beatrice Pflüger-Müller; Corina Ratiu; Lunda Gu; Kristian Helin; Gerd Geisslinger; Ingrid Fleming; Katrin Schröder; Christian Fork; Ralf P Brandes; Matthias S Leisegang
Journal:  Acta Physiol (Oxf)       Date:  2018-08-25       Impact factor: 6.311

5.  Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage.

Authors:  Xueying Zhao; Tatsuo Yamamoto; John W Newman; In-Hae Kim; Takaho Watanabe; Bruce D Hammock; Janet Stewart; Jennifer S Pollock; David M Pollock; John D Imig
Journal:  J Am Soc Nephrol       Date:  2004-05       Impact factor: 10.121

6.  Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo.

Authors:  Ding Ai; Yi Fu; Deliang Guo; Hiromasa Tanaka; Nanping Wang; Chaoshu Tang; Bruce D Hammock; John Y-J Shyy; Yi Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-10       Impact factor: 11.205

Review 7.  Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics.

Authors:  John D Imig
Journal:  Pharmacol Ther       Date:  2018-06-30       Impact factor: 12.310

Review 8.  Endothelial dysfunction and cardiovascular disease.

Authors:  R Jay Widmer; Amir Lerman
Journal:  Glob Cardiol Sci Pract       Date:  2014-10-16

9.  Mechanisms of Vascular Dysfunction in COPD and Effects of a Novel Soluble Epoxide Hydrolase Inhibitor in Smokers.

Authors:  Lucy Yang; Joseph Cheriyan; David D Gutterman; Ruth J Mayer; Zsuzsanna Ament; Jules L Griffin; Aili L Lazaar; David E Newby; Ruth Tal-Singer; Ian B Wilkinson
Journal:  Chest       Date:  2016-11-21       Impact factor: 9.410
  9 in total
  1 in total

1.  The Plasma Oxylipin Signature Provides a Deep Phenotyping of Metabolic Syndrome Complementary to the Clinical Criteria.

Authors:  Céline Dalle; Jérémy Tournayre; Malwina Mainka; Alicja Basiak-Rasała; Mélanie Pétéra; Sophie Lefèvre-Arbogast; Jessica Dalloux-Chioccioli; Mélanie Deschasaux-Tanguy; Lucie Lécuyer; Emmanuelle Kesse-Guyot; Léopold K Fezeu; Serge Hercberg; Pilar Galan; Cécilia Samieri; Katarzyna Zatońska; Philip C Calder; Mads Fiil Hjorth; Arne Astrup; André Mazur; Justine Bertrand-Michel; Nils Helge Schebb; Andrzej Szuba; Mathilde Touvier; John W Newman; Cécile Gladine
Journal:  Int J Mol Sci       Date:  2022-10-02       Impact factor: 6.208
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.